Literature DB >> 17942134

Expression of a human cytomegalovirus latency-associated homolog of interleukin-10 during the productive phase of infection.

Christina Jenkins1, Winnie Garcia, Allison Abendroth, Barry Slobedman.   

Abstract

The human cytomegalovirus UL111A region is active during both productive and latent phases of infection. During productive infection, the virus expresses ORF79, a protein with oncogenic properties, and cmvIL-10, a functional homolog of human IL-10. During latent infection of myeloid progenitor cells, an alternately spliced variant of cmvIL-10, termed latency-associated (LA) cmvIL-10 has previously been identified. To determine whether LAcmvIL-10 transcription occurs during productive infection, we performed 5' and 3' RACE to map UL111A-region transcripts in productively infected human foreskin fibroblasts (HFFs). This analysis revealed the presence of a singly spliced UL111A-region transcript predicted to encode LAcmvIL-10. This transcript was expressed in HFFs with early (beta) kinetics, a temporal class that differs from that of ORF79 (alpha kinetics) and cmvIL-10 (gamma kinetics). These data identify and map a transcript encoding a latency-associated homolog of IL-10 which is expressed by the virus during the productive phase of infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942134     DOI: 10.1016/j.virol.2007.09.002

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

Review 1.  Virus-encoded homologs of cellular interleukin-10 and their control of host immune function.

Authors:  Barry Slobedman; Peter A Barry; Juliet V Spencer; Selmir Avdic; Allison Abendroth
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

Review 2.  Viral manipulation of the host immune response.

Authors:  Allison Christiaansen; Steven M Varga; Juliet V Spencer
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

3.  Latent human cytomegalovirus enhances HIV-1 infection in CD34+ progenitor cells.

Authors:  Allen Ka Loon Cheung; Yiru Huang; Hau Yee Kwok; Min Chen; Zhiwei Chen
Journal:  Blood Adv       Date:  2017-01-16

4.  Human Cytomegalovirus UL111A and US27 Gene Products Enhance the CXCL12/CXCR4 Signaling Axis via Distinct Mechanisms.

Authors:  Carolyn C Tu; Kathleen L Arnolds; Christine M O'Connor; Juliet V Spencer
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

5.  CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138.

Authors:  Siok-Keen Tey; Felicia Goodrum; Rajiv Khanna
Journal:  J Gen Virol       Date:  2010-04-07       Impact factor: 3.891

6.  Inhibition of human cytomegalovirus immediate-early gene expression by cyclin A2-dependent kinase activity.

Authors:  Jennifer D Oduro; Ralf Uecker; Christian Hagemeier; Lüder Wiebusch
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

7.  Modulation of the Host Environment by Human Cytomegalovirus with Viral Interleukin 10 in Peripheral Blood.

Authors:  Vivian P Young; Margarette C Mariano; Carolyn C Tu; Kathryn M Allaire; Selmir Avdic; Barry Slobedman; Juliet V Spencer
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 8.  Herpesviral capture of immunomodulatory host genes.

Authors:  Günther Schönrich; Mohammed O Abdelaziz; Martin J Raftery
Journal:  Virus Genes       Date:  2017-04-27       Impact factor: 2.332

9.  Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection.

Authors:  C Jenkins; W Garcia; M J Godwin; J V Spencer; J Lewis Stern; A Abendroth; B Slobedman
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

10.  Human Cytomegalovirus-Encoded Human Interleukin-10 (IL-10) Homolog Amplifies Its Immunomodulatory Potential by Upregulating Human IL-10 in Monocytes.

Authors:  Selmir Avdic; Brian P McSharry; Megan Steain; Emma Poole; John Sinclair; Allison Abendroth; Barry Slobedman
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.